[1] |
Adjemian J, Frankland TB, Daida YG, et al. Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA. Emerg Infect Dis, 2017, 23(3): 439-447. doi:10.3201/eid2303.161827.
doi: 10.3201/eid2303.161827
pmid: 28221128
|
[2] |
Zhou L, Xu D, Liu H, et al. Trends in the Prevalence and Antibiotic Resistance of Non-tuberculous Mycobacteria in Mainland China, 2000—2019: Systematic Review and Meta-Analysis. Front Public Health, 2020, 8: 295. doi:10.3389/fpubh.2020.00295.
doi: 10.3389/fpubh.2020.00295
pmid: 32850570
|
[3] |
滕田璐, 尚园园, 黄海荣, 等. 四种常见外排泵抑制剂对克拉霉素抗脓肿分枝杆菌体外最低抑菌浓度的影响. 中华结核和呼吸杂志, 2022, 45(5): 468-474. doi:10.3760/cma.j.cn112147-20210923-00669.
doi: 10.3760/cma.j.cn112147-20210923-00669
|
[4] |
Bakuła Z, Modrzejewska M, Pennings L, et al. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii. Antimicrob Agents Chemother, 2018, 62(4): e01788-17. doi:10.1128/AAC.01788-17.
doi: 10.1128/AAC.01788-17
|
[5] |
Vilchèze C, Jacobs WR Jr. The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis. J Mol Biol, 2019, 431(18): 3450-3461. doi:10.1016/j.jmb.2019.02.016.
doi: 10.1016/j.jmb.2019.02.016
URL
|
[6] |
Aeschlimann JR, Dresser LD, Kaatz GW, et al. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother, 1999, 43(2):335-340. doi:10.1128/AAC.43.2.335.
doi: 10.1128/AAC.43.2.335
pmid: 9925528
|
[7] |
Singh M, Jadaun GP, Ramdas, et al. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res, 2011, 133(5): 535-540.
|
[8] |
Ramón-García S, Martín C, Thompson CJ, et al. Role of the Mycobacterium tuberculosis P 55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother, 2009, 53(9): 3675-3682. doi:10.1128/AAC.00550-09.
doi: 10.1128/AAC.00550-09
pmid: 19564371
|
[9] |
Kaestner KH, Randall SK, Sze H. N,N'-dicyclohexylcarbodiimide-binding proteolipid of the vacuolar H+-ATPase from oat roots. J Biol Chem, 1988, 263(3): 1282-1287.
pmid: 2891708
|
[10] |
Brown MH, Paulsen IT, Skurray RA. The multidrug efflux protein NorM is a prototype of a new family of transporters. Mol Microbiol, 1999, 31(1): 394-395. doi:10.1046/j.1365-2958.1999.01162.x.
doi: 10.1046/j.1365-2958.1999.01162.x
pmid: 9987140
|
[11] |
Poelarends GJ, Mazurkiewicz P, Konings WN. Multidrug transporters and antibiotic resistance in Lactococcus lactis. Biochim Biophys Acta, 2002, 1555(1-3): 1-7. doi:10.1016/s0005-2728(02)00246-3.
doi: 10.1016/s0005-2728(02)00246-3
pmid: 12206883
|
[12] |
Ghajavand H, Kargarpour Kamakoli M, Khanipour S, et al. Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant Mycobacterium tuberculosis: mutations versus efflux pumps. Antimicrob Resist Infect Control, 2019, 8: 70. doi:10.1186/s13756-019-0516-4.
doi: 10.1186/s13756-019-0516-4
|
[13] |
Machado D, Perdigão J, Portugal I, et al. Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant Mycobacterium tuberculosis Strains. Antibiotics (Basel), 2018, 7(1): 18. doi:10.3390/antibiotics7010018.
doi: 10.3390/antibiotics7010018
|
[14] |
Just I, Selzer J, Wilm M, et al. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature, 1995, 375(6531): 500-503. doi:10.1038/375500a0.
doi: 10.1038/375500a0
|
[15] |
Rodrigues L, Machado D, Couto I, et al. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol, 2012, 12(4): 695-700. doi:10.1016/j.meegid.2011.08.009.
doi: 10.1016/j.meegid.2011.08.009
pmid: 21871582
|
[16] |
Ng VH, Cox JS, Sousa AO, et al. Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol, 2004, 52(5): 1291-1302. doi:10.1111/j.1365-2958.2004.04078.x.
doi: 10.1111/j.1365-2958.2004.04078.x
pmid: 15165233
|
[17] |
Guo Y, Cao Y, Liu H, et al. Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China. Microbiol Spectr, 2022, 10(1): e0147521. doi:10.1128/spectrum.01475-21.
doi: 10.1128/spectrum.01475-21
|
[18] |
DeStefano MS, Shoen CM, Cynamon MH. Therapy for Mycobacterium kansasii Infection: Beyond 2018. Front Microbiol, 2018, 9: 2271. doi:10.3389/fmicb.2018.02271.
doi: 10.3389/fmicb.2018.02271
pmid: 30319580
|
[19] |
Reingewertz TH, Meyer T, McIntosh F, et al. Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug. Antimicrob Agents Chemother, 2020, 64(2): e01899-19. doi:10.1128/AAC.01899-19.
doi: 10.1128/AAC.01899-19
|
[20] |
莫凌, 张文宏, 王骥, 等. KatG基因点突变与结核分枝杆菌异烟肼耐药相关性研究. 中华传染病杂志, 2004, 22(2): 94-97. doi:10.3760/j.issn:1000-6680.2004.02.006.
doi: 10.3760/j.issn:1000-6680.2004.02.006
|
[21] |
张宗德, 马玙, 程绍基, 等. 异烟肼耐药与结核分支杆菌katG基因突变的研究. 中华结核和呼吸杂志, 1996, 19(6):346-349.
|
[22] |
张宗德, 马玙, 贾红艳. 结核分支杆菌katG基因第463位密码子突变与异烟肼耐药的研究. 中华结核和呼吸杂志, 1999, 22(3):168.
|